9 cases of multiple sclerosis (#MS) and neuromyelitis optica as a potential adverse event of #COVIDVaccination (AstraZeneca):
New relapse of multiple sclerosis (#MS) and neuromyelitis optica as a potential adverse event of #COVIDVaccination (AstraZeneca):
A report of 9 cases. The vaccination triggered a new relapse with increased disability & new brain lesions.New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19
Abstract
We report on nine patients (eight cases of MS and one case of NMOSD) who presented a disease relapse in close temporal association with their first AZD1222 vaccination dose against COVID-19. These patients had been stable for a median period of six years, with no evidence of disease activity and no change in their medication. After a median of 13 days (7 to 25 days) from vaccination, they developed a new relapse with increased disability and new lesions on magnetic resonance imaging. Although this association may be rare, it might be an adverse event of AZD1222.
Continue here:
Commenti
Posta un commento